Ozempic Injections for Weight Loss: Dosage & Biomarker Context

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) for weight loss typically requires four injections over a 16-week initial titration phase, starting at 0.25 mg weekly and escalating to the 2.4 mg maintenance dose. This structured dosing schedule allows the body to adapt while monitoring tolerability and metabolic response.

Standard dosing protocols provide a clinical baseline, but individual factors—including metabolic biomarkers, genetic predispositions in GLP-1 receptor signaling, and baseline insulin sensitivity—may influence how each person responds. PlexusDx supports precision-wellness conversations between patients and providers to evaluate treatment options informed by personalized biomarker data.

Standard Semaglutide Dosing Protocol for Weight Loss

The FDA-approved weight-loss protocol for semaglutide (branded as Wegovy) spans 16 weeks with weekly subcutaneous injections. Weeks 1–4 begin at 0.25 mg, weeks 5–8 increase to 0.5 mg, weeks 9–12 reach 1 mg, and weeks 13–16 escalate to 1.7 mg before final maintenance at 2.4 mg.

This stepwise escalation is designed to minimize gastrointestinal side effects while allowing metabolic adaptation. Many providers use this framework as a clinical foundation, though individual tolerance and response may warrant adjustments in timing or dose progression.

Dosing Progression Framework: Timeline and Clinical Milestones

The following table outlines the standard 16-week semaglutide titration schedule, key clinical markers to assess during each phase, and typical expected outcomes. This framework helps patients and providers track treatment progress and identify when dose adjustments or additional monitoring may be warranted.

Individual metabolic response, tolerability, and clinical goals should guide provider decisions about dose timing and escalation speed. Biomarkers such as fasting glucose, insulin levels, and weight trajectory inform these conversations.

Week Range	Dose (mg)	Clinical Focus	Expected Timeline
Weeks 1–4	0.25 mg weekly	Tolerance assessment, GI adaptation	Initial satiety signals emerge
Weeks 5–8	0.5 mg weekly	Appetite suppression onset, weight loss begins	Average 2–4 lb weight loss
Weeks 9–12	1 mg weekly	Increasing metabolic effect, glucose control	Average 4–8 lb additional loss
Weeks 13–16	1.7–2.4 mg weekly	Therapeutic dose achievement, sustained loss	Average 8–12 lb cumulative loss by week 16

Metabolic Biomarkers That Inform Dosing Decisions

Beyond standard dosing schedules, clinical biomarkers—including fasting insulin, HOMA-IR (insulin resistance index), C-peptide, and glucose response—can provide context for individualizing GLP-1 treatment. Patients with high baseline insulin resistance may show different tolerance and response patterns compared to those with normal insulin sensitivity.

Genetic variations in the GLP1R gene (such as rs6923761) and related metabolic pathways may predispose individuals to variable medication response. A qualified provider can interpret these predispositions alongside clinical biomarkers to support more tailored dose escalation and monitoring strategies.

Safety Considerations and Who Should Evaluate This Treatment

Semaglutide is not appropriate for all patients. Contraindications include personal or family history of medullary thyroid cancer, MEN2 syndrome, severe pancreatitis, or active diabetic retinopathy. Pregnancy is contraindicated, and individuals with gastroparesis or severe GI conditions require careful provider evaluation before treatment.

Common side effects include nausea, vomiting, and constipation, typically most pronounced during titration. A qualified healthcare provider should assess medical history, current medications, and metabolic status before initiating treatment and should monitor tolerability and clinical response throughout dosing escalation.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about individual predispositions in GLP-1 receptor signaling pathways—specifically GLP1R variants and related metabolic genes—that can support more informed conversations with a healthcare provider about treatment personalization. These predispositions should be interpreted alongside clinical biomarkers and medical history, not in isolation.

The Precision Peptide Genetic Test examines key variants including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 to reveal how genetic factors may influence GLP-1 pathway sensitivity and metabolic response. This genetic context does not predict exact medication response but may help explain individual variability in dose tolerance and efficacy outcomes observed during treatment.

When combined with clinical biomarkers—such as baseline fasting insulin, glucose levels, and weight-loss trajectory—genetic insights can support a more comprehensive evaluation with your provider. This precision-wellness approach may help guide dosing decisions and identify whether standard escalation protocols, adjusted timing, or alternative peptide compounds better align with your individual physiology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.